CTI BioPharma: FDA Approves VONJO To Treat Myelofibrosis And Thrombocytopenia In Adults
WASHINGTON (dpa-AFX) - CTI BioPharma Corp. (CTIC) said Monday that the U.S. Food and Drug Administration has approved VONJO or pacritinib for the treatment of adults with intermediate or high-risk